Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: GlobeNewswire
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford, UK, and Cambridge, MA, US, 17 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat all gonorrhoea, including multi-drug and extensively-drug resistant strains, in a poster presentation at the STI & HIV World Congress in Vancouver, Canada. “The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease,” said Dr David Roblin, President of R&D of Summit. “As shown by the preclinical data presented, our gonorrhoea-targeted new class antibiotic, SMT-571, has the potential to overcome known resistance mechanisms across global isolates, including multi- and extensively-drug resistant strains. Furt
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Summit Therapeutics (SMMT) Hurt Bronte Capital. Here's Why [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics Inc. (NASDAQ: SMMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.MarketBeat
- Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential [Yahoo! Finance]Yahoo! Finance
SMMT
Earnings
- 10/30/24 - Beat
SMMT
Sec Filings
- 10/30/24 - Form 10-Q
- 10/30/24 - Form 8-K
- 10/15/24 - Form 4
- SMMT's page on the SEC website